Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
15.5M
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-1.16M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$3.48M
-
Number of sells
-
-11
Significant Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (ACST) as of Q4 2024
11 filings reported holding ACST - Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (ACST) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 15.5M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include JPMORGAN CHASE & CO (0 shares), AIGH Capital Management LLC (0 shares), RENAISSANCE TECHNOLOGIES LLC (0 shares), Tower Research Capital LLC (TRC) (0 shares), UBS Group AG (0 shares), Royal Bank of Canada (0 shares), Activest Wealth Management (0 shares), BANK OF AMERICA CORP /DE/ (0 shares), NATIONAL BANK OF CANADA /FI/ (0 shares), and Federation des caisses Desjardins du Quebec (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.